Clinical trial
CRAFT: The NCT-PMO-1602 Phase II Trial
NCT04551521 · German Cancer Research Center, Other · Completed
Key facts
| NCT number | NCT04551521 |
|---|---|
| Title | CRAFT: The NCT-PMO-1602 Phase II Trial |
| Official title | Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II Trial |
| Lead sponsor | German Cancer Research Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic or Locally Advanced Malignancies |
| Intervention type | Drug |
| Interventions | Vemurafenib, Cobimetinib, Atezolizumab, Trastuzumab, Pertuzumab, Alectinib, Ipatasertib, Inavolisib |
| Enrollment | 72 |
| Start date | Oct 13, 2021 |
| Primary completion | Dec 30, 2024 |
| Completion | Dec 30, 2024 |
| First posted | Sep 16, 2020 |
| Last update posted | Jan 8, 2025 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: